Cytokeratin 5/14-positive breast cancer: True basal phenotype confined to BRCA1 tumors

Modern Pathology

Volumn 18, Issue 10, 2005, Pages 1321-1328

  Laakso, Mervi ^a,b   Loman, Niklas ^c   Borg, Åke ^c   Isola, Jorma ^b  

^a SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Basal phenotype; BRCA1; BRCA2; Cytokeratin; HER 2; Immunohistochemistry; Oncogene; Progenitor cell

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 8; ESTROGEN RECEPTOR; POLYMER; PROTEIN P63;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; FAMILIAL CANCER; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; ONCOGENE; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; STEM CELL;

BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; GENES, ERBB-2; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PHENOTYPE; PHOSPHOPROTEINS; RECEPTOR, ERBB-2; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 25144516817     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800456     Document Type: Article

References (35)

1. Moll R, Franke WW, Schiller DL. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
2. Boecker W, Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 2002;82:737-745.
3. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-439.
4. Malzahn K, Mitze M, Thoenes M, et al. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998;433:119-129.
5. Wetzels RHW, Kuijpers HJH, Lane EB, et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 1991;138:751-763.
6. Abd El-Rehim DM, Pinder SE, paish CE, et al. Expression of luminal and basal cytokeratins in human breast cancer. J Pathol 2004;203:661-671.
7. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-1533.
8. Boecker W, Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif 2003;36:73-84.
9. Birmbaum D, Bertucci F, Ginestier C, et al. Basal and luminal breast cancer: basic or luminous? Int J Oncol 2004;25:249-258.
10. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
11. Bánkfalvi A, Ludwig A, de-Hesselle B, et al. Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases. Mod Pathol 2004;17:1051-1061.
12. Boecker W, Moll R, Dervan P, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carsinoma in situ. J Pathol 2002;198:458-467.
13. Otterbach F, Bànkfalvi À, Berhner S, et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000;37:232-240.
14. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-1996.
15. Gordon LA, Mulligan KT, Maxwell-Jones H, et al. Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer 2003;106:8-16.
16. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
17. Sorlie T, Perou CM, Tibshirani R. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
18. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.
19. +) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-835.
20. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-1485.
21. Barbareschi M, Pecciarini L, Cangi MG, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001;25:1054-1060.
22. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002;198:417-427.
23. Wang X, Mori I, Tang W, et al. p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002;9:216-219.
24. Ribeiro-Silva A, Zambelli Ramalho LN, Britto Garcia S, et al. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 2003;127:336-340.
25. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratin 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003;443:122-132.
26. Makretsov NA, Huntsman DG, Nielsen TO, et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004;10:6143-6151.
27. Loman N, Johannsson O, Kristoffersson U, et al. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 2001;93:1215-1223.
28. Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10:4793-4798.
29. Tacha DE, Miller RT. Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue. Appl Immunohistochem Mol Morphol 2004;12:75-78.
30. Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 1998;31:205-262.
31. Clarke CL, Sandle J, Parry SC, et al. Cytokeratin 5/6 in normal human breast: lack of evidence for a stem cell phenotype. J Pathol 2004;204:147-152.
32. Angus B, Purvis J, Stock D, et al. NCL-5D3: a new monoclonal antibody recognizing low molecular weight cytokeratins effective for immunohistochemistry using fixed paraffin-embedded tissue. J Pathol 1987;153:377-384.
33. Foulkes WD. BRCA1 functions as a breast stem cell regulator. J Med Genet 2003;41:1-5.
34. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptor in hormone receptor positive primary breast cancer. J Natl Cancer Inst 2003;95:142-153.
35. Tanner M, Kapanen AI, Junttila T, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004;3:1585-1592.